Loading...

Purified anti-mouse/human CD45R/B220 Antibody

Pricing & Availability
Clone
RA3-6B2 (See other available formats)
Regulatory Status
RUO
Other Names
B220
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
1_RA3-6B2_Pure_112911
C57BL/6 mouse slenocytes were stained with purified B220 (clone RA3-6B2) (filled histogram) or rat IgG2a, κ (open histogram), followed by anti-rat IgG FITC.
  • 1_RA3-6B2_Pure_112911
    C57BL/6 mouse slenocytes were stained with purified B220 (clone RA3-6B2) (filled histogram) or rat IgG2a, κ (open histogram), followed by anti-rat IgG FITC.
  • 2_RA3-6B2_PURE_CD45R_IHC-F_091018
    C57BL/6 mouse frozen spleen section was fixed with 4% paraformaldehyde (PFA) for ten minutes at room temperature and blocked with 5% FBS for 30 minutes at room temperature. Then, the section was stained with 10 µg/mL of purified anti-mouse/human CD45R/B220 (clone RA3-6B2) and anti-mouse CD3ε (clone 500A2) Alexa Fluor® 594 (red) overnight at 4°C, followed by 2.5 µg/mL of anti-rat IgG (clone Poly4054) Alexa Fluor® 488 (green) for two hours at room temperature. Nuclei were counterstained with DAPI (blue). The image was captured by 10X objective.
  • RA3-6B2_PURE_CD45R_IHC-F_102418
    Fresh, frozen mouse spleen was stained with purified CD45R/B220 clone Ra3-6B2 conjugated and detected with a FITC CODEX™ oligonucleotide duplex (red). Samples were counterstained with TCT A647 (green). Data generated at Akoya Biosciences, Inc. using the CODEX™ technology.
Compare all formats
Cat # Size Price Quantity Check Availability Save
103201 50 µg 24€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
103202 500 µg 67€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD45R, also known as B220, is an isoform of CD45. It is a member of the protein tyrosine phosphatase (PTP) family with a molecular weight of approximately 180-240 kD. CD45R is expressed on B cells (at all developmental stages from pro-B cells through mature B cells), activated B cells, and subsets of T and NK cells. CD45R (B220) is also expressed on a subset of abnormal T cells involved in the pathogenesis of systemic autoimmunity in MRL-Faslpr and MRL-Fasgld mice. It plays a critical role in TCR and BCR signaling. The primary ligands for CD45 are galectin-1, CD2, CD3, and CD4. CD45R is commonly used as a pan-B cell marker; however, CD19 may be more appropriate for B cell specificity.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse, Human
Reported Reactivity
Cat
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Abelson murine leukemia virus-induced pre-B tumor cells
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography.
Concentration
0.5 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C.
Application

FC - Quality tested
CyTOF®, IHC-F - Verified
IHC-P, IP, Activ - Reported in the literature, not verified in house
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 106 cells in 100 µl volume. For immunohistochemistry on frozen tissue sections, a concentration range of 5.0 - 10 µg/ml is suggested. It is recommended that the reagent be titrated for optimal performance for each application.

Application Notes

Clone RA3-6B2 has been described to react with an epitope on the extracellular domain of the transmembrane CD45 glycoprotein which is dependent upon the expression of exon A and specific carbohydrate residues. Additional reported applications (for the relevant formats) include: immunoprecipitation1, in vitro and in vivo modulation of B cell responses2-4, immunohistochemistry of acetone-fixed frozen sections and formalin-fixed paraffin-embedded sections5,6, and spatial biology (IBEX)14,15.

Application References
  1. Coffman RL. 1982. Immunol. Rev. 69:5. (IP)
  2. George A, et al. 1994. J. Immunol. 152:1014. (Activ)
  3. Asensi V, et al. 1989. Immunology 68:204. (Activ)
  4. Domiati-Saad R, et al. 1993. J. Immunol. 151:5936. (Activ)
  5. Hata H, et al. 2004. J. Clin. Invest. 114:582. (IHC)
  6. Monteith CE, et al. 1996. Can. J. Vet. Res. 60:193. (IHC)
  7. Shih FF, et al. 2006. J. Immunol. 176:3438. (FC)
  8. Chang C L-T, et al. 2007. J. Immunol. 178:6984.
  9. Fazilleau N, et al. 2007. Nature Immunol. 8:753.
  10. Lang GL, et al. 2008. Blood 111:2158. PubMed
  11. Charles N, et al. 2010. Nat. Med. 16:701. (FC) PubMed
  12. del Rio ML, et al. 2011. Transpl. Int. 24:501. (FC) PubMed
  13. Murakami R, et al. 2013. PLoS One. 8:73270. PubMed
  14. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  15. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Dallari S, et al. 2017. Nat Commun. 8:14830. PubMed
  2. Wolf Y, et al. 2017. J Exp Med. 214:905. PubMed
  3. Luo W, et al. 2019. Nat Immunol. 20:736. PubMed
  4. Kobayashi A, et al. 2021. Front Immunol. 12:650856. PubMed
  5. Liu CJ, et al. 2020. Neuro Oncol. 22:1276. PubMed
  6. Calcagno DM, et al. 2020. Sci Immunol. 5: . PubMed
  7. Malinczak CA, et al. 2021. J Immunol. 206:1315. PubMed
  8. Koenig A, et al. 2022. Front Immunol. 12:791100. PubMed
  9. Valet C, et al. 2022. J Clin Invest. 132: . PubMed
  10. Avalos A, et al. 2022. JCI Insight. 7: . PubMed
  11. Campisi L, et al. 2022. Nature. 606:945. PubMed
  12. Piñeros AR, et al. 2022. Cell Rep. 39:111011. PubMed
  13. Xu C, et al. 2022. iScience. 25:105123. PubMed
  14. Moore AR, et al. 2022. Cell Rep. 41:111651. PubMed
  15. Frede A, et al. 2022. Immunity. 55:2336. PubMed
  16. Milutinovic S, et al. 2022. Cancer Res Commun. 2:1641. PubMed
  17. Hailemichael Y, et al. 2022. Cancer Cell. 40:509. PubMed
  18. Shirai T, et al. 2022. Cancer Sci. 113:3710. PubMed
  19. Kang YA, et al. 2023. J Exp Med. 220:. PubMed
  20. Mazor R, et al. 2018. Proc Natl Acad Sci U S A. 115:E733. PubMed
  21. Chartrand K, et al. 2018. Front Immunol. 1.642361111. PubMed
  22. Gern BH, et al. 2021. Cell Host Microbe. 29(4):594-606.e6. PubMed
  23. Bajaña S, et al. 2021. Front Immunol. 11:577718. PubMed
  24. Khan KA, et al. 2020. NPJ Breast Cancer. 6:29. PubMed
  25. Goel S, et al. 2017. Nature. 548:471. PubMed
  26. Fonseca JA, et al. 2018. Vaccine. 36:2799. PubMed
  27. Arnold IC, et al. 2018. J Exp Med. 215:2055. PubMed
  28. Chen L, et al. 2019. Nat Commun. 3.553472222. PubMed
  29. Periasamy S, et al. 2017. Nat Commun. 8:15564. PubMed
  30. Plumlee CR, et al. 2020. Cell Host Microbe. 29(1):68-82.e5. PubMed
  31. Mayer JU, et al. 2020. Front Immunol. 11:592325. PubMed
  32. Son YM, et al. 2020. Eur J Immunol. 50:1067. PubMed
  33. Tian K, et al. 2021. J Immunol Res. 2021:6297332. PubMed
  34. Nguyen N, et al. 2022. iScience. 25:103679. PubMed
  35. Grohmann M et al. 2018. Cell. 175(5):1289-1306 . PubMed
  36. Ng SR, et al. 2020. Proc Natl Acad Sci U S A. 117:513. PubMed
  37. Niss Arfelt K, et al. 2017. Blood. 129:866. PubMed
  38. Schafflick D, et al. 2020. Nat Commun. 247:11. PubMed
  39. Conlon TM, et al. 2020. Nature. 588:151. PubMed
  40. Stebegg M, et al. 2019. Nat Commun. 2.113194444. PubMed
  41. McLeod RL, et al. 2018. Oncotarget. 9:34459. PubMed
  42. De Schepper S et al. 2018. Cell. 175(2):400-415 . PubMed
  43. Lee JH, et al. 2022. iScience. 25:104166. PubMed
  44. Peng V, et al. 2020. J Biol Chem. 295:14866. PubMed
  45. Yang M, et al. 2020. Oncoimmunology. 9:1708064. PubMed
  46. Sugita J, et al. 2021. Nat Commun. 12:1910. PubMed
  47. Adamson SE, et al. 2018. Arterioscler Thromb Vasc Biol. 38:1020. PubMed
  48. Dubey LK, et al. 2019. Cell Rep. 27:2442. PubMed
  49. Sun H, et al. 2018. J Cell Biol. 217:1453. PubMed
  50. Chen S, et al. 2018. Immunohorizons. 0.345138889. PubMed
  51. Khan KA, et al. 2020. NPJ Breast Cancer. 6:29. PubMed
  52. Baluk P, et al. 2020. Am J Pathol. 190:2355. PubMed
  53. Suzuki Y, et al. 2021. FEBS Open Bio. 11:2619. PubMed
  54. Seelige R, et al. 2018. Sci Rep. 8:13670. PubMed
  55. Piliponsky AM, et al. 2019. Nat Immunol. 0.922916667. PubMed
  56. Zhao L, et al. 2018. Nat Med. 24:1536. PubMed
  57. Manni M, et al. 2018. Nat Immunol. 1.074305556. PubMed
  58. Stacey MA, et al. 2017. J Clin Invest. 127:1463. PubMed
  59. Quaranta V, et al. 2018. Cancer Res. 2018:5379085. PubMed
  60. Ma W, et al. 2017. Sci Rep. . 10.1038/s41598-017-15661-6. PubMed
  61. Telford W, et al. 2017. Cytometry A. 91:314. PubMed
  62. Abboud G, et al. 2018. Front Immunol. 9:1973. PubMed
  63. Mainini F, et al. 2018. Nucleic Acid Ther. 28:225. PubMed
  64. Dungubat E, et al. 2020. Nutrients. 12:00. PubMed
  65. Vukman KV, et al. 2020. J Extracell Vesicles. 10:e12023. PubMed
  66. Liu H, et al. 2020. J Immunol. 205:1207. PubMed
  67. Brown IK, et al. 2021. PLoS Pathog. 17:e1009602. PubMed
  68. Umemoto T, et al. 2017. EMBO J. 36:2390. PubMed
  69. Wan X, et al. 2018. Nature. 560:107. PubMed
  70. Cardoso F, et al. 2021. Nature. 597:410. PubMed
  71. Tran JQ, et al. 2020. Blood Adv. 4:5547. PubMed
  72. Davies CL, et al. 2019. Front Immunol. 10:1048. PubMed
  73. Shin J, et al. 2018. Diabetes. 67:1068. PubMed
  74. Lebert-Ghali C, et al. 2016. Blood. 127: 87-90. PubMed
  75. Schuler CF, et al. 2020. Allergy. 75:2279. PubMed
  76. Tao H, et al. 2021. Front Immunol. 12:623280. PubMed
  77. King IL, et al. 2017. Mucosal Immunol. 10:1160. PubMed
  78. Nagatake T, et al. 2018. Int Immunol. 30:471. PubMed
  79. Gröschel C, et al. 2017. Sci Rep.. 10.1038/s41598-017-16147-1. PubMed
  80. Murakami R, et al. 2013. PLoS One. 8:73270. PubMed
  81. Chen HW, et al. 2021. Biomedicines. 9:. PubMed
  82. Baluk P, et al. 2018. Methods Mol Biol. 1846:161. PubMed
  83. Wang HC, et al. 2017. J Immunol. 198:3149. PubMed
  84. Parigi SM, et al. 2018. Sci Rep. 0.440277778. PubMed
  85. Yoon BH, et al. 2018. Mol Cells. 41:953. PubMed
  86. Lang G, et al. 2008. Blood. 111:2158. PubMed
  87. Ikezoe T, et al. 2021. Biomolecules. 11:. PubMed
  88. Kimishima Y, et al. 2021. Nat Commun. 12:6177. PubMed
  89. Rosenbaum M, et al. 2019. Nat Commun. 2.05. PubMed
  90. Wang W, et al. 2018. J Vasc Surg. 68:1538. PubMed
  91. Kawabe T, et al. 2017. Sci Immunol. 2:eaam9315. PubMed
  92. Kwok T, et al. 2022. Front Aging. 3:838943. PubMed
  93. Yin S et al. 2019. Cancer cell. 35(2):283-296 . PubMed
  94. Akiel M, et al. 2017. Cancer Res. 77:4014. PubMed
  95. Duncan CG, et al. 2018. G3 (Bethesda). 0.892361111. PubMed
  96. Simmons S et al. 2019. Elife. 8 pii: e41239. PubMed
  97. Chung WY, et al. 2018. ALTEX. 36:29. PubMed
  98. Link CWM, et al. 2020. Front Immunol. 11:596772. PubMed
  99. Lin Z, et al. 2021. Stem Cells. 39:240. PubMed
  100. Messal HA, et al. 2020. Nat Protoc. 16:239. PubMed
  101. Mohrin M, et al. 2021. Aging Cell. 20:e13313. PubMed
  102. Schnoegl D, et al. 2022. Front Immunol. 13:909270. PubMed
  103. Englezou PC, et al. 2018. Mol Ther Nucleic Acids. 12:118. PubMed
  104. Cole C, et al. 2018. Nucleic Acids Res. 46:e62. PubMed
  105. Yamashita M, et al. 2019. Cell Stem Cell. 25:357. PubMed
  106. Diao J, et al. 2018. J Immunol. 201:1306. PubMed
  107. Chiu H, et al. 2017. Front Immunol. 0.852083333. PubMed
  108. Heib T, et al. 2021. Cell Reports. 35(6):109102. PubMed
  109. Feng X, et al. 2020. DNA Repair (Amst). 86:102754. PubMed
  110. Fujimura N, et al. 2016. J Vasc Surg. 64: 46-54. PubMed
  111. Schneppenheim J, et al. 2017. J Immunol. 199:172. PubMed
  112. Ravell JC, et al. 2020. J Clin Invest. 130:507. PubMed
  113. Ito Y, et al. 2018. J Exp Med. 215:2617. PubMed
  114. Nagashima K, et al. 2017. Biochem Biophys Res Commun. . 10.1016/j.bbrc.2017.09.004. PubMed
  115. Alrefai H, et al. 2016. Nat Commun. 7:11724. PubMed
  116. Kästele V, et al. 2021. Mucosal Immunol. 14:717. PubMed
  117. Prabakaran T, et al. 2021. EBioMedicine. 66:103314. PubMed
RRID
AB_312986 (BioLegend Cat. No. 103201)
AB_312986 (BioLegend Cat. No. 103202)

Antigen Details

Structure
Protein tyrosine phosphatase (PTP) family, 180-240 kD
Distribution

B cells, T cell subset, NK cell subset

Function
Phosphatase, T and B cell activation
Ligand/Receptor
Galectin-1, CD2, CD3, CD4
Cell Type
B cells, NK cells, T cells
Biology Area
Cell Biology, Immunology, Inhibitory Molecules, Neuroscience, Neuroscience Cell Markers
Molecular Family
CD Molecules
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Trowbridge IS, et al. 1993. Annu. Rev. Immunol. 12:85.
3. Kishihara K, et al. 1993. Cell 74:143.
4. Pulido R, et al. 1988. J. Immunol. 140:3851.

Gene ID
19264 View all products for this Gene ID 5788 View all products for this Gene ID
UniProt
View information about CD45R on UniProt.org

Related FAQs

There are no FAQs for this product.

Other Formats

View All CD45R/B220 Reagents Request Custom Conjugation
Description Clone Applications
Alexa Fluor® 594 anti-mouse/human CD45R/B220 RA3-6B2 IHC-F,FC,3D IHC
APC anti-mouse/human CD45R/B220 RA3-6B2 FC
Biotin anti-mouse/human CD45R/B220 RA3-6B2 FC,IHC-F
FITC anti-mouse/human CD45R/B220 RA3-6B2 FC
PE anti-mouse/human CD45R/B220 RA3-6B2 FC
PE/Cyanine5 anti-mouse/human CD45R/B220 RA3-6B2 FC
Purified anti-mouse/human CD45R/B220 RA3-6B2 FC,CyTOF®,IHC-F,IHC-P,IP,Activ
PE/Cyanine7 anti-mouse/human CD45R/B220 RA3-6B2 FC
APC/Cyanine7 anti-mouse/human CD45R/B220 RA3-6B2 FC
Alexa Fluor® 488 anti-mouse/human CD45R/B220 RA3-6B2 FC,IHC-F,3D IHC
Alexa Fluor® 647 anti-mouse/human CD45R/B220 RA3-6B2 FC,IHC-F,3D IHC,SB
Pacific Blue™ anti-mouse/human CD45R/B220 RA3-6B2 FC
Alexa Fluor® 700 anti-mouse/human CD45R/B220 RA3-6B2 FC
PerCP anti-mouse/human CD45R/B220 RA3-6B2 FC
PerCP/Cyanine5.5 anti-mouse/human CD45R/B220 RA3-6B2 FC
Brilliant Violet 421™ anti-mouse/human CD45R/B220 RA3-6B2 FC,IHC-F
Brilliant Violet 570™ anti-mouse/human CD45R/B220 RA3-6B2 FC
Brilliant Violet 650™ anti-mouse/human CD45R/B220 RA3-6B2 FC
Brilliant Violet 605™ anti-mouse/human CD45R/B220 RA3-6B2 FC
Brilliant Violet 785™ anti-mouse/human CD45R/B220 RA3-6B2 FC
Brilliant Violet 510™ anti-mouse/human CD45R/B220 RA3-6B2 FC,IHC-F,SB
Purified anti-mouse/human CD45R/B220 (Maxpar® Ready) RA3-6B2 FC,CyTOF®
Brilliant Violet 711™ anti-mouse/human CD45R/B220 RA3-6B2 FC
PE/Dazzle™ 594 anti-mouse/human CD45R/B220 RA3-6B2 FC
APC/Fire™ 750 anti-mouse/human CD45R/B220 RA3-6B2 FC
Brilliant Violet 750™ anti-mouse/human CD45R/B220 RA3-6B2 FC
TotalSeq™-A0103 anti-mouse/human CD45R/B220 RA3-6B2 PG
Spark Blue™ 550 anti-mouse/human CD45R/B220 RA3-6B2 FC
Spark NIR™ 685 anti-mouse/human CD45R/B220 RA3-6B2 FC
TotalSeq™-B0103 anti-mouse/human CD45R/B220 RA3-6B2 PG
Ultra-LEAF™ Purified anti-mouse/human CD45R/B220 RA3-6B2 FC,CyTOF®,IHC-F,IHC-P,IP,Activ
TotalSeq™-C0103 anti-mouse/human CD45R/B220 RA3-6B2 PG
PE/Fire™ 640 anti-mouse/human CD45R/B220 RA3-6B2 FC
APC/Fire™ 810 anti-mouse/human CD45R/B220 RA3-6B2 FC
PE/Fire™ 700 anti-mouse/human CD45R/B220 RA3-6B2 FC
Spark Violet™ 538 anti-mouse/human CD45R/B220 RA3-6B2 FC
Spark YG™ 581 anti-mouse/human CD45R/B220 RA3-6B2 FC
Spark YG™ 570 anti-mouse/human CD45R/B220 RA3-6B2 IHC-F
PE/Fire™ 810 anti-mouse/human CD45R/B220 RA3-6B2 FC
Spark Blue™ 574 anti-mouse/human CD45R/B220 Antibody RA3-6B2 FC
Spark Violet™ 423 anti-mouse/human CD45R/B220 Antibody RA3-6B2 FC
Spark Red™ 718 anti-mouse/human CD45R/B220 RA3-6B2 FC
Spark UV™ 387 anti-mouse/human CD45R/B220 RA3-6B2 FC
Spark PLUS UV395™ anti-mouse/human CD45R/B220 RA3-6B2 FC
Go To Top Version: 3    Revision Date: 08-15-2022

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account